This two-day meeting held March 2nd and 3rd, 2018 (Great Hall, St Bartholomew's Hospital, and the Haberdasher's Hall, Central London, UK) brought together an international faculty of 192 participants in the heart of London to present the latest updates in all aspects of mycology relating to human fungal diseases. To achieve this, a wide array of presentations were provided by experts, including bench scientists through to the clinicians managing patients and beyond. This special supplement provides an overview of the content of the meeting, with podcasts of a much wider range of presentations available online at [www.fungalupdate.org](http://www.fungalupdate.org). The meeting was organized by Dr Samir Agrawal and the team at Page Medical, ably supported by the scientific committee (E. Bignell, M. Ceesay, J. Lambourne, R. Manuel, P. Pfeffer, M. Richardson, P. Verweij, M. Wilks, and L. White).

The articles collated in this issue provide a walk through the host-pathogen interactions that determine the host immune response, the impact of new biological agents on immune defence against invasive fungal disease (IFD), resulting in IFD in patient groups previously considered low-risk (Chang and Levitz; Eades and Armstrong-Jones). A key clinical challenge is the diagnosis of IFD in patients considered too unwell for diagnostic tissue biopsy. Lewis White gives a comprehensive account of current fungal biomarker assays, including potential rapid point-of care tests, and a glimpse of the future directions.

How to implement fungal biomarkers into the management of patients is complex, with many factors outside of the control of the treating physician. Multiple faculty members have joined forces in the papers by de Kort et al., Stanzani et al., and Van Daele et al. giving fascinating insights into the historical development of biomarker-guided approaches, looking "beyond biomarkers" with enhanced imaging modalities and reviewing novel antifungal agents, including drugs in early phase development. All of these efforts are needed as the burden of fungal infections continues to rise concurrent with an ever-increasing susceptible population, along with the global threat of increasing fungal resistance and subsequent need for efficient antifungal stewardship.

A new session at the 13th Fungal Update was a one-day, parallel "Imaging and Infection" workshop led by radiologists and respiratory physicians. The spectrum of respiratory pathogens in immunocompromised patients is wide, yet nihilism regarding identification of opportunistic infections leads to antimicrobial polypharmacy, which given the issues mentioned above is a risky strategy. This *status quo* is being challenged by new imaging techniques and laboratory studies, combined with better understanding of how pathology can determine radiological presentation.

Steve Ellis highlighted the diagnostic limitations of the nonspecific radiological changes seen with many opportunistic infections, while classical signs, such as the halo sign, are rare. However, Periselneris and Brown show in their paper that by combining clinical history, knowledge of the host-pathogen immunological interactions and radiology, the differential diagnosis can be narrowed. Further reason for optimism is the improved diagnostic utility of evolving imaging modalities, for example, the veno-occlusive sign on computerized tomography (CT) pulmonary angiography and advances in PET imaging (Stanzani et al.). Ashraf and Lau present electromagnetic navigation bronchoscopy, a novel and exciting tool for sampling of even small peripheral pulmonary lesions.

The global burden of fungal infections is huge, and they remain a challenge to diagnose and treat. However, the advances reported here in basic immunology, clinical strategies, biomarker assays, antifungal drugs, and imaging all offer hope for the future. The impact of better imaging and investigations for suspected fungal infections will also be felt outside the disease areas in which opportunistic infections are classically an issue; equally, there is increasing interest in the roles fungal infection may play in many diseases.
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